Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5) 5
oncology (4) 4
acquired-resistance (2) 2
article (2) 2
biochemistry & molecular biology (2) 2
drug-combinations (2) 2
inhibitor (2) 2
mek inhibition (2) 2
mutation (2) 2
proteins (2) 2
resistance (2) 2
stability (2) 2
access control (1) 1
acquired resistance (1) 1
activating mutations (1) 1
addiction (1) 1
alectinib (1) 1
alk (1) 1
allosteric regulation (1) 1
anaplastic lymphoma kinase (1) 1
anaplastic lymphoma kinase - genetics (1) 1
and nsclc (1) 1
animals (1) 1
annotations (1) 1
bh3 mimetic abt-737 (1) 1
bim (1) 1
binding sites (1) 1
bond (1) 1
breast-cancer (1) 1
brigatinib (1) 1
cell biology (1) 1
cell line, tumor (1) 1
cell lines (1) 1
cell lung-cancer (1) 1
cell survival (1) 1
cells (1) 1
ceritinib (1) 1
chain (1) 1
chemistry, multidisciplinary (1) 1
chemotherapy (1) 1
coevolution (1) 1
communication (1) 1
computer security (1) 1
contact prediction (1) 1
correlated mutations/co-evolving residues (1) 1
correlation analysis (1) 1
crispr (1) 1
crizotinib (1) 1
crizotinib - administration & dosage (1) 1
crizotinib - pharmacology (1) 1
crystallography (1) 1
design (1) 1
dna (1) 1
docetaxel (1) 1
drug resistance (1) 1
drug resistance, neoplasm (1) 1
eml4-alk (1) 1
epidermal growth factor (1) 1
epidermal growth factor receptors (1) 1
ethylnitrosourea - adverse effects (1) 1
evolution (1) 1
expression (1) 1
family (1) 1
female (1) 1
fibroblast growth factor (1) 1
fibroblast growth factor receptor 1 (1) 1
fibroblast growth factor receptors (1) 1
file servers (1) 1
functionally diverse families and superfamilies (1) 1
gefitinib (1) 1
gene (1) 1
gene expression (1) 1
gene-expression (1) 1
genetic transcription (1) 1
genetics & heredity (1) 1
genomes (1) 1
growth factors (1) 1
growth-factor receptor-3 (1) 1
heterocyclic compounds (1) 1
homology (1) 1
humans (1) 1
hypertext markup language (1) 1
information-theoretic analysis (1) 1
internet server software (1) 1
k+ solution (1) 1
kinases (1) 1
lactams, macrocyclic - administration & dosage (1) 1
lactams, macrocyclic - pharmacology (1) 1
ligands (1) 1
long-range correlations (1) 1
lorlatinib (1) 1
lung cancer (1) 1
lung neoplasms - chemically induced (1) 1
lung neoplasms - drug therapy (1) 1
lung neoplasms - genetics (1) 1
major g-quadruplex (1) 1
mathematical & computational biology (1) 1
mesenchyme (1) 1
met amplification (1) 1
metastasis (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Yosshi: a web-server for disulfide engineering by bioinformatic analysis of diverse protein families
by Suplatov, D and Timonina, D and Sharapova, Y and Svedas, V
NUCLEIC ACIDS RESEARCH, ISSN 0305-1048, 07/2019, Volume 47, Issue W1, pp. W308 - W314
Disulfide bonds play a significant role in protein stability, function or regulation but are poorly conserved among evolutionarily related proteins. The Yosshi... 
CHAIN | DESIGN | STABILITY | STABILIZATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | BOND | TOOL | Web Server Issue
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. The visualCMAT: A web-server to select and interpret correlated mutations/co-evolving residues in protein families
by Suplatov, Dmitry and Sharapova, Yana and Timonina, Daria and Kopylov, Kirill and Švedas, Vytas
Journal of Bioinformatics and Computational Biology, ISSN 0219-7200, 04/2018, Volume 16, Issue 2
The visualCMAT web-server was designed to assist experimental research in the fields of protein/enzyme biochemistry, protein engineering, and drug discovery by... 
binding sites | functionally diverse families and superfamilies | Correlated mutations/co-evolving residues | structure-function relationship | physically interacting correlated pairs | allosteric regulation | long-range correlations | protein design | web-server | COEVOLUTION | SPECIFICITY | STABILITY | CONTACT PREDICTION | INFORMATION-THEORETIC ANALYSIS | EVOLUTION | SEQUENCE ALIGNMENT | MATHEMATICAL & COMPUTATIONAL BIOLOGY | SITES | STRUCTURE PREDICTION | COMMUNICATION
Journal Article
Details down arrow
3. Full Text A New G‑Quadruplex with Hairpin Loop Immediately Upstream of the Human BCL2 P1 Promoter Modulates Transcription
by Onel, Buket and Carver, Megan and Wu, Guanhui and Timonina, Daria and Kalarn, Salil and Larriva, Marti and Yang, Danzhou
Journal of the American Chemical Society, ISSN 0002-7863, 03/2016, Volume 138, Issue 8, pp. 2563 - 2570
The abnormal overexpression of the BCL2 gene is associated with many human tumors. We found a new 28-mer G-quadruplex-forming sequence, P1G4, immediately... 
BREAST-CANCER | CELLS | MAJOR G-QUADRUPLEX | DNA | PROTEIN EXPRESSION | GENE-EXPRESSION | INHIBITOR | CHEMISTRY, MULTIDISCIPLINARY | K+ SOLUTION | REGION | FAMILY | Genetic transcription | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
by Raoof, S and Mulford, IJ and Frisco-Cabanos, H and Nangia, V and Timonina, D and Labrot, E and Hafeez, N and Bilton, SJ and Drier, Y and Ji, F and Greenberg, M and Williams, A and Kattermann, K and Damon, L and Sovath, S and Rakiec, DP and Korn, JM and Ruddy, DA and Benes, CH and Hammerman, PS and Piotrowska, Z and Sequist, LV and Niederst, MJ and Barretina, J and Engelman, JA and Hata, AN
ONCOGENE, ISSN 0950-9232, 09/2019, Volume 38, Issue 37, pp. 6399 - 6413
Evolved resistance to tyrosine kinase inhibitor (TKI)-targeted therapies remains a major clinical challenge. In epidermal growth factor receptor (EGFR) mutant... 
MULTIPLE-MYELOMA | GEFITINIB | METASTASIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | ACQUIRED-RESISTANCE | CELL BIOLOGY | TO-MESENCHYMAL TRANSITION | MET AMPLIFICATION | ONCOLOGY | PATHWAY | GENETICS & HEREDITY | GROWTH-FACTOR RECEPTOR-3 | INHIBITOR | ACTIVATING MUTATIONS | Tyrosine | CRISPR | Fibroblast growth factor | Cell survival | Epidermal growth factor receptors | Small cell lung carcinoma | Mesenchyme | Lung cancer | Non-small cell lung carcinoma | Genomes | Gene expression | Drug resistance | Kinases | Epidermal growth factor | Motivation | Cell lines | Growth factors | Fibroblast growth factor receptor 1 | Protein-tyrosine kinase | Fibroblast growth factor receptors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Abstract 2130: The novel G-quadruplex with hairpin loop formed immediately upstream of the human BCL-2 P1 promoter represses BCL-2 transcription
by Onel, Buket and Wu, Guanhui and Carver, Megan and Timonina, Daria and Larriva, Marti and Yang, Danzhou
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 2130 - 2130
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Abstract 2163: Combined targeting of MEK and MCL-1 induces apoptosis and tumor regression of KRAS mutant NSCLC
by Hata, Aaron N and Siddiqui, Faria M and Gomez-Caraballo, Maria and Bilton, Samantha J and Timonina, Daria and Nangia, Varuna and Coxon, Angela and Caenepeel, Sean and Hughes, Paul
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 13 Supplement, pp. 2163 - 2163
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. The visualCMAT: A web-server to select and interpret correlated mutations/co-evolving residues in protein families
by Suplatov, Dmitry and Sharapova, Yana and Timonina, Daria and Kopylov, Kirill and Švedas, Vytas
Journal of bioinformatics and computational biology, 04/2018, Volume 16, Issue 2, p. 1840005
The visualCMAT web-server was designed to assist experimental research in the fields of protein/enzyme biochemistry, protein engineering, and drug discovery by... 
Journal Article
Details down arrow
8. Full Text Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer
by Yoda, Satoshi and Lin, Jessica J and Lawrence, Michael S and Burke, Benjamin J and Friboulet, Luc and Langenbucher, Adam and Dardaei, Leila and Prutisto-Chang, Kylie and Dagogo-Jack, Ibiayi and Timofeevski, Sergei and Hubbeling, Harper and Gainor, Justin F and Ferris, Lorin A and Riley, Amanda K and Kattermann, Krystina E and Timonina, Daria and Heist, Rebecca S and Iafrate, A. John and Benes, Cyril H and Lennerz, Jochen K and Kenudson, Mari Mino and Engelman, Jeffrey A and Johnson, Ted W and Hata, Aaron N and Shaw, Alice T
Cancer Discovery, ISSN 2159-8274, 06/2018, Volume 8, Issue 6, pp. 714 - 729
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The... 
EML4-ALK | DRUG-COMBINATIONS | GENE | ONCOLOGY | CERITINIB | OVERCOMES CRIZOTINIB RESISTANCE | ALECTINIB | ACQUIRED-RESISTANCE | OPEN-LABEL | ROS1 | CHEMOTHERAPY | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Lung Neoplasms - chemically induced | Humans | Ethylnitrosourea - adverse effects | Drug Resistance, Neoplasm | Lactams, Macrocyclic - pharmacology | Anaplastic Lymphoma Kinase - genetics | Whole Exome Sequencing | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Oncogene Proteins, Fusion - genetics | Crizotinib - pharmacology | Cell Line, Tumor | Crizotinib - administration & dosage | Female | Lactams, Macrocyclic - administration & dosage | Mice | Protein Kinase Inhibitors - pharmacology | Mutation | Index Medicus | ALK | brigatinib | crizotinib | lorlatinib | and NSCLC | Anaplastic lymphoma kinase | ceritinib | acquired resistance | alectinib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition
by Misale, Sandra and Fatherree, Jackson P and Cortez, Eliane and Li, Chendi and Bilton, Samantha and Timonina, Daria and Myers, David T and Lee, Dana and Gomez-Caraballo, Maria and Greenberg, Max and Nangia, Varuna and Greninger, Patricia and Egan, Regina K and McClanaghan, Joseph and Stein, Giovanna T and Murchie, Ellen and Zarrinkar, Patrick P and Janes, Matthew R and Li, Lian-Sheng and Liu, Yi and Hata, Aaron N and Benes, Cyril H
Clinical Cancer Research, ISSN 1078-0432, 01/2019, Volume 25, Issue 2, pp. 796 - 807
Purpose: KRAS-mutant lung cancers have been recalcitrant to treatments including those targeting the MAPK pathway. Covalent inhibitors of KRAS p.G12C allele... 
CELL LUNG-CANCER | MUTANT | MEK INHIBITION | ONCOLOGY | SELUMETINIB PLUS DOCETAXEL | RAS | TRAMETINIB | RESISTANCE | ADDICTION
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer
by Costa, Carlotta and Wang, Ye and Ly, Amy and Hosono, Yasuyuki and Ellen, Murchie and Walmsley, Charlotte S and Huynh, Tiffany and Healy, Christopher and Peterson, Rachel and Yanase, Shogo and Jakubik, Charles T and Henderson, Laura E and Damon, Leah J and Timonina, Daria and Sanidas, Ioannis and Pinto, Christopher J and Mino-Kenudson, Mari and Stone, James R and Dyson, Nicholas J and Ellisen, Leif W and Bardia, Aditya and Ebi, Hiromichi and Benes, Cyril H and Engelman, Jeffrey A and Juric, Dejan
Cancer Discovery, ISSN 2159-8274, 10/2019, p. CD-18-0830
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Exploiting MCL-1 dependency with combination MEK + MCL-1 inhibitors leads to induction of apoptosis and tumor regression in KRAS mutant non-small cell lung cancer
by Nangia, Varuna and Siddiqui, Faria M and Caenepeel, Sean and Timonina, Daria and Bilton, Samantha J and Phan, Nicole and Gomez-Caraballo, Maria and Archibald, Hannah L and Li, Chendi and Fraser, Cameron and Rigas, Diamanda and Vajda, Kristof and Ferris, Lorin A and Lanuti, Michael and Wright, Cameron D and Raskin, Kevin A and Cahill, Daniel P and Shin, John H and Keyes, Colleen and Sequist, Lecia V and Piotrowska, Zofia and Farago, Anna F and Azzoli, Christopher G and Gainor, Justin F and Sarosiek, Kristopher A and Brown, Sean P and Coxon, Angela and Benes, Cyril H and Hughes, Paul E and Hata, Aaron N
Cancer discovery, ISSN 2159-8274, 12/2018, Volume 8, Issue 12, pp. 1598 - 1613
BH3 mimetic drugs, which inhibit pro-survival BCL-2 family proteins, have limited single-agent activity in solid tumor models. The potential of BH3 mimetics... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Exploiting MCL1 dependency with combination MEK + MCL1 inhibitors leads to induction of apoptosis and tumor regression in KRAS-Mutant non–small cell lung cancer
by Nangia, Varuna and Siddiqui, Faria M and Caenepeel, Sean and Timonina, Daria and Bilton, Samantha J and Phan, Nicole and Gomez-Caraballo, Maria and Archibald, Hannah L and Li, Chendi and Fraser, Cameron and Rigas, Diamanda and Vajda, Kristof and Ferris, Lorin A and Lanuti, Michael and Wright, Cameron D and Raskin, Kevin A and Cahill, Daniel P and Shin, John H and Keyes, Colleen and Sequist, Lecia V and Piotrowska, Zofia and Farago, Anna F and Azzoli, Christopher G and Gainor, Justin F and Sarosiek, Kristopher A and Brown, Sean P and Coxon, Angela and Benes, Cyril H and Hughes, Paul E and Hata, Aaron N
Cancer Discovery, ISSN 2159-8274, 12/2018, Volume 8, Issue 12, pp. 1598 - 1613
BH3 mimetic drugs, which inhibit prosurvival BCL2 family proteins, have limited single-agent activity in solid tumor models. The potential of BH3 mimetics for... 
DRUG-COMBINATIONS | MEK INHIBITION | ONCOLOGY | BIM | RESISTANCE | REGULATORS | BH3 MIMETIC ABT-737 | PROTEINS | EXPRESSION | DOCETAXEL | TRAMETINIB GSK1120212
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.